LPCN Lipocine (LPCN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001535955
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter
What the filings say about LPCN
Insiders, 180 days
+$82.2K net bought
1 buyer
Lipocine insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Lipocine Inc. insiders bought a net $82.2K of stock across 17 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Sep 29, 2026.
- +25.4% median (+25.4% mean) 90-day return after 2 previous buys.
- The trade is 6.6% of the 241,365 shares held after it.
- No other insider bought within 30 days.
- 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Higuchi John W. bought about $35.6K of LPCN on Sep 30, 2026; 17 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Sep 28, 2026.
- +25.4% median (+25.4% mean) 90-day return after 2 previous buys.
- The trade is 4.0% of the 225,395 shares held after it.
- No other insider bought within 30 days.
- 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Higuchi John W. bought about $19.4K of LPCN on Sep 29, 2026; 17 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 7, 2026.
- +25.4% median (+25.4% mean) 90-day return after 2 previous buys.
- The trade is 5.8% of the 216,358 shares held after it.
- No other insider bought within 30 days.
- 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Higuchi John W. bought about $27.1K of LPCN on Sep 28, 2026; 17 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 6, 2026.
- The trade is 19.6% of the 203,797 shares held after it.
- 1 other insider bought within 30 days.
- 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Higuchi John W. bought about $81.2K of LPCN on Apr 7, 2026; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 75.1% of the 163,797 shares held after it.
- 1 other insider bought within 30 days.
- 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Higuchi John W. bought about $252.1K of LPCN on Apr 6, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$82.2K over 180 days
+$82.2K over 90 days
more than 76% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
-82.3% year over year
below 87% of Pharma & Biotech
Margin
-487.1% net margin
below 78% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.5% of the float short (float per yahoo 2026-10-26) · 2.3 days to cover · settled 2026-09-30
below 71% of Pharma & Biotech
What changed in the last 30 days
Oct 1Director Higuchi John W. bought $82.2K (3 trades, Sep 28 to Sep 30)
Watch LPCN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-48.8%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LPCN: institutional holders (13F)
13F holdings, latest reported quarter
810,000 sh
$2.1M
508,556 sh
$1.3M
294,989 sh
$755.2K
230,823 sh
$590.9K
140,487 sh
$359.6K
Congress trades in LPCN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LPCN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LPCN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
TIFF MULTI-ASSET FUND
$15.9K position · as of 2026-06-30
0.0%
Dimensional US Core Equity 1 ETF
$10.8K position · as of 2026-07-31
0.0%
U.S. Social Core Equity 2 Portfolio
$5.8K position · as of 2026-07-31
0.0%
Fidelity Extended Market Index Fund
$67.0K position · as of 2026-05-31
0.0%
U.S. Sustainability Core 1 Portfolio
$13.1K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$148.2K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 2
0 active
2
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mahesh Patel
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$986.3K
$1.1M
$488.4K
+19%
n/a
2024
$761.8K
$754.7K
$377.2K
-28%
n/a
2023
$860.3K
$720.1K
$353.4K
-59%
n/a
2022
$883.9K
$538.8K
$325.0K
-60%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $82.2K bought by insiders over 180 days, 17 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LPCN financials
Revenue growth
-82.3%
XBRL, annual
Net margin
-487.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LPCN
| FY Dec 2025 | $2.0M |
| FY Dec 2024 | $11.2M |
| FY Dec 2023 | -$2.9M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $190.1K |
| Mar 2026 | $119.4K |
| Dec 2025 | $1.1M |
| Sep 2025 | $114.6K |
| Jun 2025 | $622.8K |
| Mar 2025 | $93.9K |
| Dec 2024 | $3.5M |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-755.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LPCN
| FY Dec 2025 | -487.2% |
| FY Dec 2024 | +0.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -207.1% |
| Sep 2025 | n/a |
| Jun 2025 | -354.1% |
| Mar 2025 | n/a |
| Dec 2024 | +51.1% |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM LPCN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$11.9M |
| FY Dec 2022 | -$12.1M |
| FY Dec 2021 | -$4.4M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $1.7M |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.11x
long-term 2022-03-31 (51 months older than the period end) plus current 2022-03-31 (51 months older than the period end); equity 2026-06-30
Debt to equity LPCN
| FY Dec 2025 | 0.16x |
| FY Dec 2024 | 0.11x |
| FY Dec 2023 | 0.11x |
| FY Dec 2022 | 0.06x |
| FY Dec 2021 | 0.09x |
| Jun 2026 | 0.11x |
| Mar 2026 | 0.10x |
| Dec 2025 | 0.16x |
| Sep 2025 | 0.16x |
| Jun 2025 | 0.14x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.11x |
| Sep 2024 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-4.83x
TTM operating cash flow over long-term 2022-03-31 (51 months older than the period end) plus current 2022-03-31 (51 months older than the period end)
Cash flow to debt LPCN
| FY Dec 2025 | -4.22x |
| FY Dec 2024 | -0.53x |
| FY Dec 2023 | -5.13x |
| FY Dec 2022 | -5.17x |
| FY Dec 2021 | -1.11x |
| Jun 2026 | -4.83x |
| Mar 2026 | -4.34x |
| Dec 2025 | -4.22x |
| Sep 2025 | -2.22x |
| Jun 2025 | -2.15x |
| Mar 2025 | -2.42x |
| Dec 2024 | -0.53x |
| Sep 2024 | -2.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-61.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LPCN
| FY Dec 2025 | -54.3% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | -58.4% |
| FY Dec 2022 | -26.5% |
| FY Dec 2021 | -2.1% |
| Jun 2026 | -61.0% |
| Mar 2026 | -54.4% |
| Dec 2025 | -54.3% |
| Sep 2025 | -32.9% |
| Jun 2025 | -23.5% |
| Mar 2025 | -24.9% |
| Dec 2024 | +0.0% |
| Sep 2024 | -19.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-55.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LPCN
| FY Dec 2025 | -48.7% |
| FY Dec 2024 | +0.0% |
| FY Dec 2023 | -54.0% |
| FY Dec 2022 | -23.9% |
| FY Dec 2021 | -1.6% |
| Jun 2026 | -55.9% |
| Mar 2026 | -49.9% |
| Dec 2025 | -48.7% |
| Sep 2025 | -29.8% |
| Jun 2025 | -21.7% |
| Mar 2025 | -23.4% |
| Dec 2024 | +0.0% |
| Sep 2024 | -17.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LPCN
| FY Dec 2025 | n/a |
| FY Dec 2024 | -6.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -6.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-64.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LPCN
| FY Dec 2025 | -58.5% |
| FY Dec 2024 | -5.6% |
| FY Dec 2023 | -63.8% |
| FY Dec 2022 | -29.3% |
| FY Dec 2021 | +9.6% |
| Jun 2026 | -64.6% |
| Mar 2026 | -57.7% |
| Dec 2025 | -58.5% |
| Sep 2025 | -37.9% |
| Jun 2025 | -29.1% |
| Mar 2025 | -30.0% |
| Dec 2024 | -5.6% |
| Sep 2024 | -25.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LPCN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$9.2M
market value at close 2026-10-23 on 2026-08-03 shares, plus long-term 2022-03-31 (51 months older than the period end) plus current 2022-03-31 (51 months older than the period end), minus cash 2026-06-30
Enterprise value LPCN
| FY Dec 2025 | $41.7M |
| FY Dec 2024 | $22.2M |
| FY Dec 2023 | $12.4M |
| FY Dec 2022 | $598.0M |
| FY Dec 2021 | $1.5B |
| Jun 2026 | $18.4M |
| Mar 2026 | $55.6M |
| Dec 2025 | $41.7M |
| Sep 2025 | $13.9M |
| Jun 2025 | $13.2M |
| Mar 2025 | $16.0M |
| Dec 2024 | $22.2M |
| Sep 2024 | $22.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield LPCN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -80.1% |
| FY Dec 2022 | -2.0% |
| FY Dec 2021 | -0.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -20.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LPCN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.0M | $11.2M | -$2.9M | $500.0K |
| Operating income | -$10.4M | -$1.2M | -$17.9M | -$12.1M |
| Net income | -$9.6M | $10.0K | -$16.4M | -$10.8M |
| EPS (diluted) | -1.69 | n/a | -3.14 | -2.15 |
| Operating cash flow | -$9.8M | -$1.2M | -$11.9M | -$12.0M |
| Cash | $5.2M | $6.2M | $4.8M | $3.1M |
SEC XBRL, fiscal years, as known on 2026-10-27
LPCN Stock Sonar score 6/7 axes
Find similar shapesCompareLPCN ranks highest on risk and compliance (79th percentile) and insider conviction (66th), and lowest on growth (12th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LPCN filings, in plain words
Are Lipocine insiders buying or selling LPCN?
In the 180 days to 2026-10-27, Lipocine insiders were net buyers, a net $82.2K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-27, Lipocine insiders were net buyers of LPCN, a net $82.2K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
